Tagrisso Approved for Some With Locally Advanced, Unresectable Stage III NSCLC Following Chemoradiation

The FDA has approved osimertinib (Tagrisso, AstraZeneca) for adult patients with locally advanced, unresectable ...

SEPTEMBER 25, 2024

For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines

In patients with unresectable epidermal growth factor receptor−mutated (EGFRm), stage III non-small cell lung ...

JULY 10, 2024

Tagrisso Approved With Chemotherapy for EGFR-mutated NSCLC

The FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for ...

FEBRUARY 16, 2024

Overall Survival Benefit Establishes New Standard in Resected EGFR-Mutated NSCLC

Three years ago, the phase 3 ADAURA trial associated osimertinib (Tagrisso, AstraZeneca) with a large disease-free ...

JUNE 12, 2023

Tagrisso Approved as First Adjuvant Treatment of EGFR-Mutated NSCLC

The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with ...

JANUARY 3, 2021

Thoughts on Adjuvant Osimertinib: The ADAURA Trial Report

Nasser Hanna, MD, and Steven Vogl, MD, discuss the findings from the ADAURA NSCLC trial presented at ASCO 2020 and ...

SEPTEMBER 21, 2020

FDA Approves Tagrisso for EGFR T790M Mutation–Positive Metastatic NSCLC

The drug was approved for the treatment of patients with metastatic EGFR T790M mutation–positive NSCLC.

MARCH 31, 2017

Osimertinib Shows Longer PFS in T790M-Positive Advanced NSCLC

Osimertinib demonstrated superior efficacy compared with platinum therapy plus pemetrexed in patients with ...

DECEMBER 28, 2016

Blood-Based T790M Companion Diagnostic Test for Tagrisso Approved

Approved as a blood-based companion diagnostic for osimertinib (Tagrisso, AstraZeneca) to provide an alternative ...

SEPTEMBER 30, 2016